caffeine has been researched along with Dyspnea in 9 studies
Dyspnea: Difficult or labored breathing.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective of the TROCADERO is to evaluate the effect of caffeine versus placebo on ticagrelor-associated dyspnea, measured by the visual analog scale area under the curve in patients with ongoing ticagrelor treatment after an acute coronary syndrome event." | 9.20 | Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. ( Braun, OÖ; Christersson, C; Grove, EL; Halvorsen, S; James, SK; Lindholm, D; Storey, RF; Varenhorst, C, 2015) |
| "We measured breathlessness and exercise tolerance in 12 patients with chronic airways obstruction, moderate or severe breathlessness, and low or normal arterial carbon dioxide tension, after the patients received dihydrocodeine, alcohol, caffeine, or placebo (through double-blind administration)." | 9.05 | Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. ( Geddes, DM; Gellert, A; Gross, ER; Johnson, M; Shah, S; Woodcock, AA, 1981) |
| "The primary objective of the TROCADERO is to evaluate the effect of caffeine versus placebo on ticagrelor-associated dyspnea, measured by the visual analog scale area under the curve in patients with ongoing ticagrelor treatment after an acute coronary syndrome event." | 5.20 | Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. ( Braun, OÖ; Christersson, C; Grove, EL; Halvorsen, S; James, SK; Lindholm, D; Storey, RF; Varenhorst, C, 2015) |
| "We measured breathlessness and exercise tolerance in 12 patients with chronic airways obstruction, moderate or severe breathlessness, and low or normal arterial carbon dioxide tension, after the patients received dihydrocodeine, alcohol, caffeine, or placebo (through double-blind administration)." | 5.05 | Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. ( Geddes, DM; Gellert, A; Gross, ER; Johnson, M; Shah, S; Woodcock, AA, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, SSY | 1 |
| Furtado, RHM | 1 |
| Venkateswaran, RV | 1 |
| Nicolau, JC | 1 |
| Gurmu, Y | 1 |
| Bhatt, DL | 1 |
| Storey, RF | 2 |
| Steg, PG | 1 |
| Magnani, G | 1 |
| Goto, S | 1 |
| Dellborg, M | 1 |
| Kamensky, G | 1 |
| Isaza, D | 1 |
| Aylward, P | 1 |
| Johanson, P | 1 |
| Bonaca, MP | 1 |
| Lindholm, D | 2 |
| James, S | 1 |
| Andersson, J | 1 |
| Braun, OÖ | 2 |
| Heller, S | 1 |
| Henriksson, P | 1 |
| Lauermann, J | 1 |
| Öhagen, P | 1 |
| Varenhorst, C | 2 |
| Christersson, C | 1 |
| Halvorsen, S | 1 |
| Grove, EL | 1 |
| James, SK | 1 |
| FINK, T | 1 |
| FIORE, G | 1 |
| Woodcock, AA | 1 |
| Gross, ER | 1 |
| Gellert, A | 1 |
| Shah, S | 1 |
| Johnson, M | 1 |
| Geddes, DM | 1 |
| Fujii, T | 1 |
| Sasaki, H | 1 |
| Nishimura, H | 1 |
| Blamoutier, J | 1 |
| Mot, JC | 1 |
| Travagli, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor - A Double-blinded, Placebo-controlled, Randomized, Multicenter, Development Phase II Study[NCT02311088] | Phase 2 | 26 participants (Actual) | Interventional | 2014-12-31 | Terminated (stopped due to Too low enrolment rate) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
4 trials available for caffeine and Dyspnea
| Article | Year |
|---|---|
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female | 2020 |
Caffeine and incidence of dyspnea in patients treated with ticagrelor.
Topics: Adenosine; Aged; Caffeine; Drug Monitoring; Dyspnea; Female; Humans; Male; Middle Aged; Myocardial I | 2018 |
Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr.
Topics: Acute Coronary Syndrome; Adenosine; Caffeine; Dose-Response Relationship, Drug; Double-Blind Method; | 2015 |
Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases.
Topics: Alcoholic Beverages; Caffeine; Carbon Dioxide; Clinical Trials as Topic; Codeine; Double-Blind Metho | 1981 |
5 other studies available for caffeine and Dyspnea
| Article | Year |
|---|---|
PRE-WORKOUT SUPPLEMENT INDUCED CARDIAC ISCHAEMIA IN A YOUNG FEMALE.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Dietary Supplements; Dyspnea; Emergency Service, | 2020 |
[A new way of therapeutic control of pulmonary and cardiac dyspnea with neocajod].
Topics: Caffeine; Dyspnea; Heart; Iodides; Procaine | 1953 |
[Sedative effect of the mixture felsol in the dyspnea of asthmatics & cardiac patients].
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Asthma; Caffeine; Cardiac Glycosides; Dyspnea; H | 1958 |
Teratogenicity of caffeine in mice related to its mode of administration.
Topics: Abnormalities, Drug-Induced; Animals; Caffeine; Cleft Palate; Clubfoot; Dyspnea; Fingers; Gestationa | 1969 |
[Advantage of a new therapeutic agent for respiratory dyspneic diseases].
Topics: Asthma; Bronchial Diseases; Bronchodilator Agents; Caffeine; Dyspnea; Male; Parasympatholytics; Theo | 1970 |